Name | (6R)-5,10-methylenetetrahydrofolic acid |
---|---|
Synonyms |
UNII:0SXY5ET48B
5,10-methylenetetrahydrofolate 5,10-Methylenetetrahydrofolic acid folitixorin Tetrahydromethylenefolate L-glutamic acid, N-[4-(3-amino-5,6,6a,7-tetrahydro-1-hydroxyimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]- N-[4-(3-amino-1-hydroxy-5,6,6a,7-tetrahydroimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]-L-glutamic acid (2S)-2-[[4-(3-amino-1-oxo-4,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl)benzoyl]amino]pentanedioic acid L-Glutamic acid, N-[4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]- CH2H4folate N5,N10-Methyl-enetetrahydrofolic Acid N-[4-(3-Amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]-L-glutamic acid |
Description | Folitixorin (5,10-methylenetetrahydrofolate) is a cofactor and an analog of leucovorin. Folitixorin is a promising agent for modulation of 5-FU cytotoxicity in adjuvant cancer research[1][2]. |
---|---|
Related Catalog | |
In Vitro | 5,10-methylenetetrahydrofolate reductase (MTHFR) catalyzes the conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahy-drofolate, which is the major circulating form of folate[3]. |
In Vivo | A colon adenocarcinoma cell suspension is inoculated intrahepatically in a rodent experimental model. Intravenous 5-FU (30 mg/kg) in combination with Folitixorin (15 mg/kg or 30 mg/kg) is administered after 1, 2, 3, 4 and 7 days. 5-FU in combination with Folitixorin (regardless of folate-dose) eliminats tumor take[1]. |
References |
Density | 1.8±0.1 g/cm3 |
---|---|
Molecular Formula | C20H23N7O6 |
Molecular Weight | 457.440 |
Exact Mass | 457.170990 |
PSA | 194.97000 |
LogP | -2.87 |
Index of Refraction | 1.801 |
Storage condition | -20°C |